Results 221 to 230 of about 240,598 (262)

Ethnomedicinal Uses, Phytochemistry, Pharmacological Activities, and Toxicology of the Subfamily Gomphrenoideae (Amaranthaceae): A Comprehensive Review

Chemistry &Biodiversity, EarlyView.
ABSTRACT The subfamily Gomphrenoideae is composed of about 480 accepted species, many of which have been historically used as medicinal plants, reason why they have been studied in terms of chemical profile, biological activity, and safety. This review consolidates the advances in research on this subfamily over the past 47 years, emphasizing its ...
Dayanna Isabel Araque Gelves, Giulia Cristina de Andreoli Souza, Alvaro Jose Hernandez Tasco, Marcos José Salvador   +3 more
wiley   +1 more source

Effect of vitamin B6 on the synthesis and degradation of aspartate aminotransferase in chicken embryo fibroblasts.

, 1987
CP Sharma, Heinz Gehring
openalex   +1 more source

Pharmacokinetics and Safety Evaluation of a New Generic Sitafloxacin: A Phase I Bioequivalence Study in Healthy Chinese Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Sitafloxacin is a new antibiotic drug belonging to the fourth generation quinolone antibiotics. The aim of this study was to evaluate the pharmacokinetics (PK), safety profiles, and bioequivalence of test and reference 50‐mg sitafloxacin tablets under fasting and fed conditions.
Yongfang Lei, Pan Luo, Yuzhu Chen, Liuliang Xue, Donglin Zhang, Xingxing Qi, Yinian Fang, Hengyi Yu, Zheng He, Qin Zuo, Chang Liu, Dong Liu, Xinhua Ren, Qian Chen   +13 more
wiley   +1 more source

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen, Yamato Sano, Xiaohong Wang, Shuiyi Hu, Junichi Tabira, Xin Luo, Hiroki Yoshimatsu, John Prybylski, Myron Chu, Haiyan Li, Kenji Takazawa   +10 more
wiley   +1 more source

Mitochondrial aspartate aminotransferase in nonalcoholic cirrhosis

, 1989
G Cadiot, Ink O, Audrey Boutron, P Hänny, Pierre Laurent‐Puig, Camille Buffet   +5 more
openalex   +1 more source

Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Alzheimer's disease (AD), characterized by β‐amyloid (Aβ) plaques and neurofibrillary tangles, is the leading cause of dementia globally. Donanemab is a humanized immunoglobulin G1 in development as a treatment to slow AD progression. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PKs), and immunogenicity of donanemab
Junyu Xu, Nan Zhao, Yihui Wang, Ivelina Gueorguieva, Chenxi Qian, Yimin Cui   +5 more
wiley   +1 more source

Modification of aspartate aminotransferase with heavy atoms and with coenzyme analogs

, 1980
Jane Ann Schmidt
openalex   +1 more source

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick‐Sanders, Randa Hareedy, Louise Harkness, Claudia Leemereise, Kjersten Offenbecker, Christina Donatti, Darin B. Brimhall, Christian Schwabe, Craig Boyle, Michael A. Hassman, Steve Knowles, Ronald D'Amico, William R. Spreen   +16 more
wiley   +1 more source

Interactions among mitochondrial aspartate aminotransferase, malate dehydrogenase, and the inner mitochondrial membrane from heart, hepatoma, and liver.

, 1990
Jan K. Teller, Leonard A. Fahien, Enrique Valdiviá   +2 more
openalex   +1 more source

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This study (NCT04537715) investigated itraconazole (strong cytochrome P450 [CYP] 3A inhibitor) and rifampin (strong CYP3A inducer) on tazemetostat pharmacokinetics. In Part 1, patients received tazemetostat 400 mg orally on Days 1, 15, and 36, and 400 mg twice daily on Days 3‐14 and Days 21‐35.
Yingxue Chen, Renli Teng, Attila Szanto, Apoorva Kapopara, Rajat Bannerji, Julien Ogier, Devalingam Mahalingam   +6 more
wiley   +1 more source